Activity Summary:
Methamphetamine-associated pulmonary arterial hypertension (MA-PAH) is a serious and increasingly recognized subtype of pulmonary arterial hypertension linked to methamphetamine use. In this on-demand clinical snippet, Dr. Vijay Balasubramanian delves into the epidemiology, clinical characteristics, and hemodynamic challenges of MA-PAH. Participants will gain insights into the global and U.S. trends of methamphetamine use, its associated cardiopulmonary risks, and the mechanisms contributing to vascular toxicity. In addition, this activity addresses current gaps in treatment strategies, challenges in patient adherence, and the need for more comprehensive management approaches, equipping healthcare providers with knowledge to better diagnose and manage this complex condition.

Activity Summary:
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this podcast episode, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.

This podcast aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.

Activity Summary:
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this on-demand video, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.

This activity aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.

Activity Summary:
Pulmonary Arterial Hypertension (PAH) remains a significant clinical challenge, particularly in complex cases like PAH-related right heart failure (RHF) and PAH in pregnancy, both of which are associated with high morbidity and mortality. This educational slide kit is designed to address these unmet needs by exploring two complex case studies: a PAH patient with RHF necessitating hospitalization, and a pregnant patient with PAH. These cases provide a platform for discussing the complexities involved in selecting initial treatment regimens, recognizing signs of disease progression, and making timely adjustments to treatment plans.

This lecture library aims to enhance clinicians' understanding of routine follow-up measures to prevent clinical deterioration and to familiarize them with emerging evidence that can inform management strategies. It also delves into specific protocols for managing pregnant patients with PAH, a particularly high-risk group, ensuring that healthcare providers are equipped to navigate these challenging scenarios with confidence. By addressing these diverse learning objectives, this slide kit seeks to improve outcomes in patients facing the most severe manifestations of PAH.

Activity Summary:
In this on-demand clinical snippet, Dr. Marc Humbert provides an in-depth exploration of managing atypical pulmonary arterial hypertension (PAH) patients, who often present with complex profiles, including older age, cardiovascular comorbidities, and pulmonary issues. Throughout the video, Dr. Humbert emphasizes the importance of recognizing these non-standard PAH cases and applying personalized, ambitious treatment strategies to improve outcomes. He also highlights the need for comprehensive multidisciplinary evaluations, regular risk assessments, and the use of all approved PAH therapies tailored to individual patient needs, as well as underscores the significance of ongoing research and emerging therapies in advancing the care of these diverse patient populations.

Activity Summary:
Pulmonary Arterial Hypertension (PAH) poses significant clinical challenges due to its complex nature and the risk of rapid disease progression. This educational slide kit addresses some of these complex challenges by focusing on two key patient scenarios: a newly diagnosed PAH patient and a high-risk patient with inadequate response to current treatments. These cases emphasize the importance of selecting the appropriate initial treatment regimens and highlights the routine follow-up measures necessary to prevent clinical deterioration.

The slide kit aims to equip clinicians with the skills to recognize parameters associated with disease progression and to make informed decisions about treatment modifications for high-risk patients. By exploring evidence-based strategies and various treatment options, this educational initiative seeks to enhance clinicians' abilities to manage PAH effectively, ultimately improving patient outcomes.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational podcasts will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.

Activity Summary:
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In these mini-modules, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand video presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.

Activity Summary:
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this podcast episode, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.

Activity Summary:
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this webcast archive, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.

Activity Summary:
Recent data suggests that PAH is now frequently diagnosed in older patients who often present with cardiovascular (CV) comorbidities. Many patients present with CV comorbidities that are uncontrolled, creating a management dilemma for the treating physician. This slide set presents two case studies discussing the clinical approach as well as how to control comorbidities and their impact on the pulmonary circulation with the best treatment approach for this population.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles, resulting in right heart failure and death within 2-3 years of diagnosis if untreated. Despite advances in the diagnosis and treatment of PAH over the last two decades, the prognosis is still poor. Early recognition of disease, institution of effective PAH disease-specific therapy optimized for disease severity, and comprehensive care in specialized centers hold the promise of improving the outcome of patients. PAH is often misdiagnosed or unrecognized in clinical practice and delaying treatment options can worsen outcomes and survival. Diagnostic tests are needed to be done on anyone with unexplained dyspnea and suspected PAH. This slide kit is designed for primary care providers and other non-specialists, using case-based, interactive discussion on tools to improve diagnosis of PAH and the importance of early referral.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
PH is currently divided into World Health Organization (WHO) groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This slide set presents the latest research in diagnosing and managing Group 2-5 in patients, including a discussion of the distinctions in specific groups – CTEPH, PH-ILD, PH-COPD.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

The incidence of PH is known to increase among patients with ILD over the course of disease, however, there is a significant overlap of symptoms between fibrotic lung disease and PH. This is known to result in delayed detection and diagnosis. Clinicians need education on the signs and symptoms and how to screen for and detect PH early among patients with ILD. Although right heart catheterization is required to confirm the diagnosis of PH-ILD, other non-invasive and invasive approaches are useful in enabling an early and accurate diagnosis. Additionally, while there have been new insights into assessing and predicting the severity of PH among patients with ILD, mild PH among patients with ILD has been associated with poor outcomes. Identifying patients that have mild PH is therefore pivotal to improving outcomes with treatment. The development and approval of inhaled treprostinil has been an important milestone in PH-ILD. Indeed, new evidence and updates from ongoing clinical trials continue to be presented and published for the treatment of PH-ILD. To improve confidence among practitioners regarding the use of inhaled treprostinil, it is critical that they are abreast with the latest evidence and expert insights. In this on-demand video presentation Dr. Aaron Waxman will walk through examples of using and optimizing inhaled treprostinil therapy in clinical cases.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. The Lecture Library offers various topics that can be accessed for AMA, ANCC or ACPE credit. Select your topic of interest and complete the pre/posttest and evaluation.

Continue to visit the Lecture Library series throughout 2024 to view updates from new publications and conference updates. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a podcast discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a roundtable discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

This activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Talking COPD is a webcast series that highlights the very latest clinical data in chronic obstructive pulmonary disease. Slides are developed and presented by leading COPD expert physicians and further reviewed and approved by the planning committee.

Chronic obstructive pulmonary disease (COPD) imposes significant impact beyond the lungs, including quality of life, health status, daily activities, physical activity, sleep, and comorbidities such as anxiety and depression. Given the increasing recognition of, and importance attributed to, patients’ and caregivers’ views and preferences on their disease and its management, it is important to identify and understand patients’ perception of COPD symptoms. Additionally, diagnosis and treatment of COPD are rapidly changing. In this on-demand video presentation, our expert faculty review how the understanding and implementation of recent advances is important for delivering optimal patient care.

Activity Summary:
The Pulmonary Hypertension Association (PHA)-Accredited PH Care Centers (PHCC) program began in late 2011 with the goal to raise the overall quality of care and improve outcomes in patients with this life-threatening disease. Accreditation is based on a center’s overall commitment to PH patients, breadth of health care professionals involved and scope of services provided. Two types of centers will be accredited: Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP). Both will have demonstrated a commitment to providing expert-level care based on published consensus guidelines. PHCCs have the opportunity to enroll PH patients into the Pulmonary Hypertension Association Registry (PHAR) patient registry to evaluate trends and practice patterns to determine which treatments work best. Moreover, in the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis, and treatment of PAH. While no therapies have been approved to target new mechanisms of action in more than 15 years, multiple phase 2 and phase 3 clinical trials of novel therapies are underway. Therapeutic trials represent the front line of clinical progress, and becoming a clinical trial investigator in PH can further help deliver more life-changing therapies to patients with PH who need them.

This AMA/ANCC/ACPE accredited, on-demand video addresses some key questions on accredited PH Care Centers and what it takes to become a clinical trial investigator.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms with novel therapeutic compounds in development. In this on-demand video presentation, our PAH experts will review practice-changing results presented at the 2023 ATS, ERS, and CHEST meetings to assess their potential future incorporation into clinical practice for patients with PAH.